Abstract:<span class="paragraphSection">BackgroundAlthough treatment modalities for non-small cell lung cancer (NSCLC) are rapidly evolving, there is insufficient evidence that novel drugs reach elderly patients (aged ≥ 70 years) and improve their outcomes. The purpose of this study was to evaluate the access to treatment in the elderly population with stage IV NSCLC in a real life setting and its impact on survival (OS) over the past 10 years.MethodsWe compared elderly and younger patients with stage IV NSCLC treated at our tertiary cancer centre and its affiliated smaller hospitals. We collected patients and tumor characteristics such as age at diagnosis, gender, smoking history, histology, molecular subtyping, PDL1 expression status and data on treatment types as well as lines. We grouped the enrolled patients into four same size cohorts based on time and age at diagnosis: patients diagnosed 2005-2007 (elderly cohort-I) and 2015-2016 (elderly cohort-II) were compared to cohorts of patients <70 years old diagnosed during the same time periods (young cohorts-I and -II). The characteristics were analysed using Chi-square Test and survival related endpoints with Kaplan-Meier model. A log-rank test was used to test the equality of the survivor functions and a z-Test to assess the differences in survival proportions.Results499 NSCLC cases were retrospectively analysed. Median OS significantly improved in both, the elderly and the young cohorts, over time. OS in the elderly cohort-I and -II was slightly lower (3.7 months and 5.3 months) compared to the young cohorts-I and -II (7.8 and 12.1 months). In the young group 12-months OS was significantly improved over the last 10 years (34% [95%CI 27%-42%] and 52% [95%CI 43%-61%], p = 0.049). There was no significant improvement in the elderly cohorts (18% [95%CI 11%-25% vs. 31% [95%CI 22%-39%], p = 0.29). Therapy with any line of systemic treatment modalities remained lower in the elderly cohorts as compared to younger patients (53% versus 78%).ConclusionsWe observed a significant improvement in OS over the past 10 years in young patients, whereas a similar benefit was not found for the elderly. Our findings highlight a strong need in studying this growing population separately in elderly specific clinical trials.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureS. Schmidt: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: MSD; Research grant / Funding (institution): BMS; Research grant / Funding (institution): AstraZeneca; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: TAKEDA; Travel / Accommodation / Expenses: Boehringer Ingelheim. M. Fruh: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. All other authors have declared no conflicts of interest.</span>

Efficacy of Platinum Drugs in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer and Their Effects on Prognosis and Survival.

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical efficacy of Gimeracil and Oteracil Porassium Capsules combined with Cisplatin concomitant radiotherapy and radiotherapy treatment for elderly patients with advanced non-small cell lung cancer

The evaluations of different age advanced non-small-cell lung cancer patients treated with docetaxel plus platinum combination chemotherapy

Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]

Analysis of Survival Data in Patients with Advanced Non-Small-Cell Lung Cancer Aged 60 Years and Over

Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.

First Line Chemotherapy with Weekly Docetaxel and Cisplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

Efficacy and Safety of First-Line Pemetrexed Plus Carboplatin Followed by Single-Agent Pemetrexed Maintenance in Elderly Chinese Patients with Non-Squamous Non-Small-cell Lung Cancer

The Role of Expression of Nrf2 in Predicting Chemoresistance and Prognosis in Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based First-Line Chemotherapy

[A Retrospective Analysis: Comparison of the Clinical Characteristics and Prognosis in Elderly and Young Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.].

Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage Ⅳ Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN Study

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Prognostic Factors in Older Patients with Advanced Non-Small Cell Lung Cancer in China.

Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer

The Efficacy and Toxicity of Chemotherapy in the Elderly with Advanced Pancreatic Cancer

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer

Does progress achieved in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) reach the elderly population?

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer